Skip to main content

Orphan Drugs and Rare Diseases

  • Reference work entry
  • First Online:
Principles and Practice of Clinical Trials

Abstract

There are approximately 8,000 recognized rare diseases affecting close to 30 million people in the United States. Sponsors choosing to engage in research and development of drugs for rare diseases, known as orphan drugs, face challenges and opportunities that are unique to orphan drug development. Small population size, disease heterogeneity, and unknown natural histories, among other factors, must be considered when designing clinical trials for orphan drugs. Additionally, sponsors need to consider the quality and quantity of clinical trial information needed to support the approval of an orphan drug. To further understand these unique challenges, sponsors should partner with patient groups who can provide disease-specific perspectives and experiences, as well as conduct natural history studies, to better inform the design and evaluation of results from clinical trials. Novel technologies are changing the clinical trial landscape which provide sponsors a unique opportunity to employ novel, lifesaving technologies that can truly “cure” rare diseases. Incentives provided by the Orphan Drug Act and other FDA policies, such as market exclusivity, priority review vouchers, and tax credits, recognize the unique status of orphan drugs and serve to stimulate the development of these products.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Subscribe and save

Springer+ Basic
EUR 32.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or Ebook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 499.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 599.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Similar content being viewed by others

References

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Frank J. Sasinowski .

Editor information

Editors and Affiliations

Section Editor information

Rights and permissions

Reprints and permissions

Copyright information

© 2022 Springer Nature Switzerland AG

About this entry

Check for updates. Verify currency and authenticity via CrossMark

Cite this entry

Valentine, J.E., Sasinowski, F.J. (2022). Orphan Drugs and Rare Diseases. In: Piantadosi, S., Meinert, C.L. (eds) Principles and Practice of Clinical Trials. Springer, Cham. https://doi.org/10.1007/978-3-319-52636-2_253

Download citation

Publish with us

Policies and ethics